Adherence to Adalimumab Was Not Improved by a Reminder-Based Intervention with an Electronic Needle Container

[1] Ford AC(2011)Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis Am J Gastroenterol 106 644-659

[2] Sandborn WJ(2009)Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn’ s disease (Cochrane review) Cochrane Database Syst Rev 19 2098-2110

[3] Khan KJ(2013)Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis Inflamm Bowel Dis 135 1493-1499

[4] Hanauer SB(2008)Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study Gastroenterology 19 4344-4350

[5] Talley NJ(2013)Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn’s disease and rheumatoid arthritis: results of a systematic review World J Gastroenterol 19 1528-1533

[6] Moayyedi P(2013)Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review Inflamm Bowel Dis 24 2053-2061

[7] Behm BW(2018)Nonadherence to biologic therapies in inflammatory bowel disease Inflamm Bowel Dis 113 276-286

[8] Bickston J(2018)Defining an optimal adherence threshold for patients taking subcutaneous anti-TNFs for inflammatory bowel diseases Am J Gastroenterol 25 2303-2310

[9] Costa J(2009)Good and poor adherence: optimal cut-point for adherence measures using administrative claims data Curr Med Res Opin 26 314-320

[10] Magro F(2020)Risk factors for medication nonadherence to self-injectable biologic therapy in adult patients with inflammatory bowel disease Inflamm Bowel Dis 10 549-555

[1] Ford AC(2011)Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis Am J Gastroenterol 106 644-659

[2] Sandborn WJ(2009)Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn’ s disease (Cochrane review) Cochrane Database Syst Rev 19 2098-2110

[3] Khan KJ(2013)Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis Inflamm Bowel Dis 135 1493-1499

[4] Hanauer SB(2008)Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study Gastroenterology 19 4344-4350

[5] Talley NJ(2013)Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn’s disease and rheumatoid arthritis: results of a systematic review World J Gastroenterol 19 1528-1533

[6] Moayyedi P(2013)Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review Inflamm Bowel Dis 24 2053-2061

[7] Behm BW(2018)Nonadherence to biologic therapies in inflammatory bowel disease Inflamm Bowel Dis 113 276-286

[8] Bickston J(2018)Defining an optimal adherence threshold for patients taking subcutaneous anti-TNFs for inflammatory bowel diseases Am J Gastroenterol 25 2303-2310

[9] Costa J(2009)Good and poor adherence: optimal cut-point for adherence measures using administrative claims data Curr Med Res Opin 26 314-320

[10] Magro F(2020)Risk factors for medication nonadherence to self-injectable biologic therapy in adult patients with inflammatory bowel disease Inflamm Bowel Dis 10 549-555